The fat disappears faster than the skin can retract
In the space between a drug's official profile and the bodies it transforms, a quiet reckoning is unfolding. Thousands of Ozempic users in Brazil and beyond are documenting on social media the physical consequences of rapid weight loss — deflated gluteal tissue, clumps of shed hair — changes the manufacturer has not formally recognized. The drug does what it promises, yet the full human cost of that promise is being written not in clinical literature, but in the testimonies of those living inside the transformation.
- Users are losing not just weight but volume and hair — changes that strike at appearance and self-image in ways no prescription label warned them about.
- TikTok has become an unofficial adverse-event registry, with photographs of sagging skin and handfuls of fallen hair accumulating into a parallel safety profile.
- Scientists point to caloric deficits, protein shortfalls, vitamin depletion, and cortisol disruption as the likely culprits — consequences of how fast the weight disappears, not of the molecule itself.
- Novo Nordisk has not acknowledged gluteal atrophy or hair shedding as recognized side effects, leaving a widening gap between corporate documentation and lived experience.
- Despite being approved in Brazil only for type 2 diabetes, Ozempic is widely used off-label for cosmetic weight loss, and that gap in oversight is where these undocumented consequences are accumulating.
Ozempic — the semaglutide-based drug manufactured by Novo Nordisk — has become a cultural phenomenon in weight loss circles, particularly among social media users seeking rapid results. In Brazil, it holds official approval only for type 2 diabetes, yet widespread off-label use for cosmetic weight loss has made it a household name.
On TikTok, users have begun documenting physical changes that fall entirely outside the drug's official safety profile. One woman described losing 27 kilograms in nine months only to find her buttocks had visibly shrunk. Others have posted images of hair falling out in clumps. These accounts have multiplied into a growing, unsanctioned conversation about consequences the manufacturer has not formally recognized.
Specialists offer explanations rooted in the mechanics of rapid weight loss itself. When fat disappears quickly from the gluteal region, skin may lack the elasticity to retract — an effect worsened by age and the magnitude of weight shed, but potentially mitigated by protein intake and strength training. Hair loss, meanwhile, likely stems from caloric deficits depriving the body of vitamins and proteins essential to hair growth, or from cortisol-related disruption of the hair growth cycle.
The drug's official label does carry serious warnings — nausea, pancreatitis, hypoglycemia, diabetic eye disease — but gluteal atrophy and hair shedding appear nowhere in it. Users are not claiming the drug caused these changes directly; they understand rapid weight loss is the mechanism. What they are insisting is that when a medication accelerates weight loss this dramatically, the downstream physical consequences deserve acknowledgment.
What emerges is a portrait of a gap: between what clinical trials document and what bodies experience, between approved indication and actual use, between manufacturer guidance and the testimony accumulating daily on social media. The drug delivers its promise — weight is lost — but the full shape of that loss is being mapped not by science, but by the people living it.
Ozempic has become a household name in weight loss circles, particularly among celebrities and social media users seeking rapid results. The drug, which contains the active ingredient semaglutide and is manufactured by Novo Nordisk, works by mimicking a natural hormone called GLP-1 that signals fullness to the brain and slows stomach digestion. The combination makes people feel less hungry and lose weight more quickly. In Brazil, the medication received official approval from the national health authority for treating type 2 diabetes, but it has become widely used off-label for cosmetic weight loss instead.
On TikTok and other social platforms, users have begun documenting side effects that the manufacturer does not officially recognize. One woman reported losing 27 kilograms over nine months, only to find that her buttocks had visibly shrunk. Others have posted photographs showing significant hair loss, some capturing the physical evidence of strands falling out in clumps. These accounts have multiplied across the platform, creating a growing conversation about consequences that fall outside the drug's official safety profile.
The gluteal changes appear to be a direct consequence of how the body loses weight under the drug's influence. When fat disappears rapidly from the buttocks—a region where many people carry substantial subcutaneous fat—the skin may not have time to retract, leaving a sagging appearance. The severity depends on several factors: the person's age, the total amount of weight shed, and their skin's natural elasticity. Younger skin with better elasticity tends to bounce back more effectively. However, the effect is not inevitable. Adequate protein intake and consistent strength training can help preserve or rebuild muscle mass in the area, counteracting the deflated look.
Hair loss appears to stem from a different mechanism. Specialists point to several possible causes: the rapid weight loss creates a significant caloric deficit that can deprive the body of essential vitamins and proteins needed for hair growth. Some experts suggest the drug's effect on cortisol—the stress hormone—may temporarily shut down the hair growth cycle. Either way, the hair shedding is not listed in the official package insert as a recognized side effect.
The official safety profile of Ozempic does include serious risks. The drug's labeling documents gastrointestinal problems like nausea, vomiting, bloating, constipation, and diarrhea. It can cause headaches and weakness. More concerning are the potential for dangerously low blood sugar, pancreatic inflammation, worsening of diabetic eye disease, and allergic reactions. These documented risks exist regardless of whether someone is taking the drug for its approved indication or using it off-label for weight loss.
What makes the current situation notable is the gap between official acknowledgment and lived experience. Novo Nordisk has not formally recognized gluteal atrophy or hair loss as side effects of semaglutide use. Yet thousands of people are reporting these changes on social media, creating a parallel conversation about the drug's real-world consequences. The users documenting these changes are not claiming the drug caused them directly—they understand that rapid weight loss itself is the culprit. But they are pointing out that when a medication causes weight loss this quickly, certain physical consequences follow, and those consequences deserve attention and discussion.
The broader context is that Ozempic remains officially approved in Brazil only for diabetes management, yet it has become a de facto weight loss drug for people without diabetes. This off-label use continues despite the documented risks and despite the emerging reports of unwanted physical changes. The drug works as intended—people do lose weight—but the full picture of what that weight loss looks like on the human body is being documented not by clinical trials or manufacturer guidance, but by users themselves, sharing their experiences online.
Notable Quotes
Hair loss may stem from vitamin deficiencies, protein insufficiency, caloric deficit, or cortisol-related hormonal disruption— Medical specialists cited in reports
The Hearth Conversation Another angle on the story
Why are people experiencing these specific changes—the buttock loss and hair shedding—if the drug itself isn't causing them directly?
Because semaglutide causes such rapid weight loss that the body can't always keep up. When you lose 27 kilograms in nine months, your skin and tissues don't have time to adjust. The fat disappears faster than the skin can retract, and the body pulls nutrients away from non-essential functions like hair growth to manage the metabolic shock.
But couldn't someone just exercise and eat well to prevent these effects?
In theory, yes. Protein and strength training can help preserve muscle and skin elasticity. But the drug itself suppresses appetite so aggressively that many users struggle to eat enough protein in the first place. You're fighting the medication's own mechanism.
So Novo Nordisk isn't acknowledging these side effects at all?
Not officially. They list the gastrointestinal problems, the blood sugar risks, the pancreatic concerns. But the cosmetic changes—the sagging skin, the hair loss—those aren't in the official documentation. Yet thousands of people are experiencing them and posting about it.
Does that mean the drug is unsafe?
It means the conversation about what "safe" means is incomplete. The drug does what it's supposed to do. But when you use it off-label for weight loss in people without diabetes, you're accepting risks that weren't part of the original approval. And you're accepting physical changes that nobody warned you about.
What happens next for these users?
Some will adjust their diet and exercise to mitigate the effects. Others will accept the changes as the price of weight loss. But the real question is whether Novo Nordisk will eventually acknowledge what's happening and provide guidance, or whether users will keep learning about these consequences from each other on social media.